BMS-275183-induced gene expression patterns in head and neck carcinoma

American Journal of Otolaryngology - Head and Neck Medicine and Surgery

Volumn 28, Issue 5, 2007, Pages 309-315

  Yoo, George H ^a   Tran, Vivian R ^a   Lemonnier, Lori A ^a   Ezzat, Waleed H ^a   Subramanian, Geetha ^a   Piechocki, Marie P ^a   Ensley, John F ^a,b   Lonardo, Fulvio ^b   Kim, Harold ^a   Lin, Ho Sheng ^a,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BMS 275183; CASPASE 3; CYCLIN A; CYCLIN B1; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P27; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

ANNEXIN A5; APOPTOSIS; BLOTTING, WESTERN; BRIDGED COMPOUNDS; CELL CYCLE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM PROTEINS; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 34548385778     PISSN: 01960709     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjoto.2006.10.001     Document Type: Article

References (58)

1. Al-Sarraf M., LeBlanc M., Giri P.G., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 16 4 (1998) 1310-1317
2. Wendt T.G., Grabenbauer G.G., Rodel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 16 4 (1998) 1318-1324
3. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 1 (2003) 92-98
4. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91 24 (1999) 2081-2086
5. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324 24 (1991) 1685-1690
6. Lefebvre J.L., Chevalier D., Luboinski B., et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88 13 (1996) 890-899
7. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 19 (2004) 1945-1952
8. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 19 (2004) 1937-1944
9. Kish J.A., Benedetti J.K., Balcerzak S.P., et al. Feasibility trial of postoperative radiotherapy and cisplatin followed by three courses of 5-FU and cisplatin in patients with resected head and neck cancer: a Southwest Oncology Group study. Cancer J Sci Am 5 5 (1999) 307-311
10. Sparano J.A. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer 1 1 (2000) 32-40 discussion 41-2
11. Belani C.P. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer. Oncology (Huntingt) 11 8 Suppl 8 (1997) 42-45
12. Kaye S.B., and Vasey P.A. Docetaxel in ovarian cancer: phase III perspectives and future development. Semin Oncol 29 3 Suppl 12 (2002) 22-27
13. Posner M.R., Glisson B., Frenette G., et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 19 4 (2001) 1096-1104
14. Nemunaitis J., Khuri F., Ganly I., et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 19 2 (2001) 289-298
15. Colevas A.D., Norris C.M., Tishler R.B., et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 17 11 (1999) 3503-3511
16. Colevas A.D., Busse P.M., Norris C.M., et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 16 4 (1998) 1331-1339
17. Posner M.R. Docetaxel in squamous cell cancer of the head and neck. Anticancer Drugs 12 Suppl 1 (2001) S21-S24
18. Schrijvers D., and Vermorken J.B. Role of taxoids in head and neck cancer. Oncologist 5 3 (2000) 199-208
19. Luck H.J., Scholz U., Kuhnle H., et al. UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer. Oncology (Williston Park) 13 7 Suppl 3 (1999) 74-76
20. Mastalerz H., Cook D., Fairchild C.R., et al. The discovery of BMS-275183: an orally efficacious novel taxane. Bioorg Med Chem 11 20 (2003) 4315-4323
21. Rose W.C., Long B.H., Fairchild C.R., et al. Preclinical pharmacology of BMS-275183, an orally active taxane. Clin Cancer Res 7 7 (2001) 2016-2021
22. Rose W.C., and Wild R. Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts. Clin Cancer Res 10 21 (2004) 7413-7417
23. Broker L.E., de Vos F.Y., van Groeningen C.J., et al. Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. Clin Cancer Res 12 6 (2006) 1760-1767
24. Yeudall W.A., Jakus J., Ensley J.F., et al. Functional characterization of p53 molecules expressed in human squamous cell carcinomas of the head and neck. Mol Carcinog 18 2 (1997) 89-96
25. Yoo G.H., Piechocki M.P., Ensley J.F., et al. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clin Cancer Res 8 12 (2002) 3910-3921
26. Kamen B.A., Rubin E., Aisner J., et al. High-time chemotherapy or high time for low dose. J Clin Oncol 18 16 (2000) 2935-2937
27. Zanelli G.D., Quaia M., Robieux I., et al. Paclitaxel as a radiosensitiser: a proposed schedule of administration based on in vitro data and pharmacokinetic calculations. Eur J Cancer 33 3 (1997) 486-492
28. Liebmann J.E., Cook J.A., Lipschultz C., et al. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 68 6 (1993) 1104-1109
29. Belani C.P. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer. Semin Oncol 29 3 Suppl 12 (2002) 4-9
30. Malingre M.M., Beijnen J.H., and Schellens J.H. Oral delivery of taxanes. Invest New Drugs 19 2 (2001) 155-162
31. Sparreboom A., van Asperen J., Mayer U., et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 94 5 (1997) 2031-2035
32. van Asperen J., van Tellingen O., Sparreboom A., et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 76 9 (1997) 1181-1183
33. van Asperen J., van Tellingen O., van der Valk M.A., et al. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res 4 10 (1998) 2293-2297
34. Meerum J., Terwogt M., Malingre M.M., et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 5 11 (1999) 3379-3384
35. Bissery M.C. Preclinical evaluation of new taxoids. Curr Pharm Des 7 13 (2001) 1251-1257
36. Polizzi D., Pratesi G., Monestiroli S., et al. Oral efficacy and bioavailability of a novel taxane. Clin Cancer Res 6 5 (2000) 2070-2074
37. Blagosklonny M.V., and Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83 2 (1999) 151-156
38. Chadebech P., Truchet I., Brichese L., et al. Up-regulation of cdc2 protein during paclitaxel-induced apoptosis. Int J Cancer 87 6 (2000) 779-786
39. Giannakakou P., Robey R., Fojo T., et al. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 20 29 (2001) 3806-3813
40. Papadimitrakopoulou V.A., Shin D.M., and Hong W.K. Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis. Cancer Metastasis Rev 15 1 (1996) 53-76
41. Tsai C.M., Yu D., Chang K.T., et al. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J Natl Cancer Inst 87 9 (1995) 682-684
42. Yu D., and Hung M.C. Role of erbB2 in breast cancer chemosensitivity. Bioessays 22 7 (2000) 673-680
43. Sirotnak F.M., Zakowski M.F., Miller V.A., et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6 12 (2000) 4885-4892
44. Baselga J., Norton L., Albanell J., et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58 13 (1998) 2825-2831
45. Stone A.A., and Chambers T.C. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res 254 1 (2000) 110-119
46. Subbaramaiah K., Hart J.C., Norton L., et al. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem 275 20 (2000) 14838-14845
47. Okano J., and Rustgi A.K. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J Biol Chem 276 22 (2001) 19555-19564
48. Lieu C.H., Liu C.C., Yu T.H., et al. Role of mitogen-activated protein kinase in taxol-induced apoptosis in human leukemic U937 cells. Cell Growth Differ 9 9 (1998) 767-776
49. Seidman R., Gitelman I., Sagi O., et al. The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells. Exp Cell Res 268 1 (2001) 84-92
50. Bacus S.S., Gudkov A.V., Lowe M., et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20 2 (2001) 147-155
51. Wang L.G., Liu X.M., Kreis W., et al. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44 5 (1999) 355-361
52. Haldar S., Basu A., and Croce C.M. Bcl2 is the guardian of microtubule integrity. Cancer Res 57 2 (1997) 229-233
53. Berchem G.J., Bosseler M., Mine N., et al. Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2. Anticancer Res 19 1A (1999) 535-540
54. Pucci B., Bellincampi L., Tafani M., et al. Paclitaxel induces apoptosis in Saos-2 cells with CD95L upregulation and Bcl-2 phosphorylation. Exp Cell Res 252 1 (1999) 134-143
55. Roth W., Wagenknecht B., Grimmel C., et al. Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest. Br J Cancer 77 3 (1998) 404-411
56. Nimmanapalli R., Perkins C.L., Orlando M., et al. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 61 2 (2001) 759-763
57. Odoux C., Albers A., Amoscato A.A., et al. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer. Int J Cancer 97 4 (2002) 458-465
58. Piechocki M.P., Lonardo F., Ensley J.F., et al. Anticancer activity of docetaxel in murine salivary gland carcinoma. Clin Cancer Res 8 3 (2002) 870-877